Cargando…
Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
OBJECTIVE: The efficacy of therapeutic vaccines against HIV-1 infection has been modest. New inerts to redirect responses to vulnerable sites are urgently needed to improve these results. DESIGN: We performed the first-in-human clinical trial with naked mRNA (iHIVARNA) combining a dendritic cell act...
Autores principales: | Leal, Lorna, Guardo, Alberto C., Morón-López, Sara, Salgado, Maria, Mothe, Beatriz, Heirman, Carlo, Pannus, Pieter, Vanham, Guido, van den Ham, Henk Jan, Gruters, Rob, Andeweg, Arno, Van Meirvenne, Sonja, Pich, Judit, Arnaiz, Joan Albert, Gatell, Josep M., Brander, Christian, Thielemans, Kris, Martínez-Picado, Javier, Plana, Montserrat, García, Felipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221380/ https://www.ncbi.nlm.nih.gov/pubmed/30289805 http://dx.doi.org/10.1097/QAD.0000000000002026 |
Ejemplares similares
-
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix †
por: de Jong, Wesley, et al.
Publicado: (2019) -
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy
por: de Jong, Wesley, et al.
Publicado: (2019) -
Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy
por: de Jong, Wesley, et al.
Publicado: (2019) -
Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice
por: Joe, Patrick Tjok, et al.
Publicado: (2019) -
Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial
por: Leal, Lorna, et al.
Publicado: (2021)